性取向与不同种族和族裔群体皮肤癌终生患病率
该横断面研究利用2014-2021年美国行为危险因素监测系统数据,分析不同种族和族裔群体中性取向与皮肤癌终生患病率的差异。结果显示,性少数男性总体皮肤癌终生患病率高于异性恋男性(7.4% vs 6.8%;AOR,1.16;95% CI,1.02-1.33),且这种差异在西班牙裔和非西班牙裔黑人男性中更明显;性少数女性在西班牙裔和非西班牙裔黑人中患病率高于异性恋女性,但在非西班牙裔白人女性中较低。
要点
- 性少数男性皮肤癌终生患病率总体高于异性恋男性(7.4% vs 6.8%;AOR,1.16;95% CI,1.02-1.33)。
- 西班牙裔和非西班牙裔黑人男性中,性少数者皮肤癌患病率显著高于异性恋者。
- 性少数女性在不同种族中差异方向不一致,需个体化评估。
核心结论
- 性少数与异性恋成人皮肤癌终生患病率的差异因种族和族裔及个体性身份而异。
- 西班牙裔和非西班牙裔黑人性少数女性及男性皮肤癌患病率高于异性恋对应人群。
研究设计与样本
- 横断面研究,使用2014年1月1日至2021年12月31日美国行为危险因素监测系统数据。
- 共纳入1 512 400名美国成人,其中异性恋女性805 161人(53.2%),性少数女性38 933人(2.6%),异性恋男性638 651人(42.2%),性少数男性29 655人(2.0%)。
- 种族和族裔构成:西班牙裔6.6%,非西班牙裔亚裔/太平洋岛民/夏威夷人3.4%,非西班牙裔黑人7.5%,非西班牙裔白人78.2%,其他种族和族裔4.3%。
- 平均年龄(标准误)为48.5(0.03)岁(≥80岁受访者年龄数据不完整)。
主要发现
- 性少数男性皮肤癌终生患病率总体高于异性恋男性(7.4% vs 6.8%;AOR,1.16;95% CI,1.02-1.33)。
- 西班牙裔男性中,性少数者皮肤癌终生患病率高于异性恋者(4.0% vs 1.6%;AOR,3.81;95% CI,1.96-7.41)。
- 非西班牙裔黑人男性中,性少数者皮肤癌终生患病率高于异性恋者(1.0% vs 0.5%;AOR,2.18;95% CI,1.13-4.19)。
- 非西班牙裔白人女性中,性少数者皮肤癌终生患病率低于异性恋者(7.8% vs 8.5%;AOR,0.86;95% CI,0.76-0.97)。
- 西班牙裔女性中,性少数者皮肤癌终生患病率高于异性恋者(2.1% vs 1.8%;AOR,2.46;95% CI,1.28-4.70);非西班牙裔黑人女性中,性少数者高于异性恋者(1.8% vs 0.5%;AOR,2.33;95% CI,1.01-5.54)。
临床怎么用
- 临床应关注性少数人群的皮肤癌风险,尤其在西班牙裔和非西班牙裔黑人中。
- 筛查和公共卫生干预需考虑种族、族裔与性取向的交互差异。
局限性
- 横断面设计无法推断因果关系。
- 皮肤癌患病率为自我报告,可能存在回忆偏倚。
- 年龄数据在≥80岁受访者中不完整。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Sexual minority (SM) persons have been found to have differential rates of skin cancer, but limited data exist on differences across racial and ethnic groups and by individual sexual identities. OBJECTIVE: To examine differences by sexual orientation in the lifetime prevalence of skin cancer among US adult females and males across racial and ethnic groups and by individual sexual identity. DESIGN, SETTING, AND PARTICIPANTS: This cross-sectional study used data from the Behavioral Risk Factor Surveillance System from January 1, 2014, to December 31, 2021, for US adults from the general population. Data were analyzed from December 1, 2023, to March 1, 2024. MAIN OUTCOMES AND MEASURES: Self-reported lifetime prevalence of skin cancer by sexual orientation. Age-adjusted prevalence and adjusted prevalence odds ratios (AORs) compared heterosexual and SM adults in analyses stratified by individual race. RESULTS: Of 1 512 400 participants studied, 805 161 (53.2%) were heterosexual females; 38 933 (2.6%), SM females; 638 651 (42.2%), heterosexual males; and 29 655 (2.0%), SM males. A total of 6.6% of participants were Hispanic; 3.4%, non-Hispanic Asian, Pacific Islander, or Hawaiian; 7.5%, non-Hispanic Black; 78.2%, non-Hispanic White; and 4.3%, other race and ethnicity. Mean (SE) age was 48.5 (0.03) years (incomplete data for age of respondents ≥80 years). The lifetime prevalence of skin cancer was overall higher among SM males compared with heterosexual males (7.4% vs 6.8%; AOR, 1.16; 95% CI, 1.02-1.33), including specifically among Hispanic males (4.0% vs 1.6%; AOR, 3.81; 95% CI, 1.96-7.41) and non-Hispanic Black males (1.0% vs 0.5%; AOR, 2.18; 95% CI, 1.13-4.19) in analyses stratified by race and ethnicity. Lifetime prevalence rates were lower among SM females compared with heterosexual females among non-Hispanic White females (7.8% vs 8.5%; AOR, 0.86; 95% CI, 0.76-0.97) and were higher among Hispanic (2.1% vs 1.8%; AOR, 2.46; 95% CI, 1.28-4.70) and non-Hispanic Black (1.8% vs 0.5%; AOR, 2.33; 95% CI, 1.01-5.54) females in analyses stratified by race and ethnicity. CONCLUSIONS AND RELEVANCE: In this cross-sectional study of US adults, differences in the lifetime prevalence of skin cancer among SM adults compared with heterosexual adults differed across racial and ethnic groups and by individual sexual identity among both females and males. Both Hispanic and non-Hispanic Black and SM females and males had higher rates of skin cancer compared with their heterosexual counterparts. Further research addressing the individual factors contributing to these differences is needed to inform screening guidelines and public health interventions focused on these diverse, heterogeneous populations.
引用
- Rypka KJ, Wendland ZD, Steele MV, et al. Sexual Orientation and Lifetime Prevalence of Skin Cancer Across Racial and Ethnic Groups. JAMA Dermatol. 2024. PMID: 39018081. doi:10.1001/jamadermatol.2024.2097
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。